Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.

acute health-related quality of life leukemia myelodysplastic syndromes myeloid natural language processing patient preference patient-centric qualitative research social media

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
22 11 2019
Historique:
received: 09 04 2019
accepted: 23 08 2019
revised: 01 08 2019
entrez: 23 11 2019
pubmed: 23 11 2019
medline: 26 6 2020
Statut: epublish

Résumé

Until recently, treatment options were limited for patients with acute myeloid leukemia and myelodysplastic syndrome (AML and MDS) who are ineligible for intensive chemotherapy. Owing to the condition's rapid progression, it is difficult to identify what is most important to patients when making treatment decisions. Patients' needs can be better addressed by gaining a deeper understanding of their perspectives, which is valuable in the decision-making process. The Food and Drug Administration recently encouraged the use of social media as a tool to gain insight on patients' perspectives regarding symptoms experienced and the impacts of their disease. This study aimed to use disease-specific social media posts by patients with AML or MDS who are ineligible for intensive chemotherapy and their caregivers to capture factors they feel are most important, and to provide current evidence to inform and characterize these perspectives. Posts by patients with AML or MDS and their caregivers were extracted from publicly available discussions on 3 large AML- or MDS-specific sites. These posts were manually reviewed to only include patients who are ineligible for intensive chemotherapy. A total of 1443 posts from 220 AML patients/caregivers and 2733 posts from 127 MDS patients/caregivers met the study inclusion criteria. A qualitative data analysis (QDA) of a sample of 85 patients'/caregivers' posts was conducted to identify themes, and a targeted QDA of posts from 79 users focused on treatment decision discussions. Posts were manually reviewed, and relevant text segments were coded and grouped into categories and overall themes. Eighty-six percent (73/85) of users in the overall QDA had relevant information about the key objectives. The most commonly discussed treatment experience theme was the humanistic burden of AML or MDS in terms of emotional/physical impact and impact on family (86%, 63/73 of users), followed by treatment decisions (56%, 41/73) and unmet needs (50%, 37/73). In the QDA of treatment decisions, 60 posts from 45 users contained relevant information. Patients commonly reported the desire to reach specific milestones, including birthdays and weddings. They wished for a better quality of life over quantity of life, did not want the risk of suffering from side effects, and expressed a clear preference to be at home rather than in a hospital or care home. This study was a novel application of disease-specific social media. It highlighted experiences in the current treatment of AML and MDS, including information gaps, patient/caregiver uncertainty, and the importance of understanding patients'/caregivers' goals and opinions. A clear finding from this research was the importance of reaching certain personal life goals and being at home with family and friends. The analysis showed that patients/caregivers face additional challenges, including humanistic impacts and a lack of information regarding treatment options.

Sections du résumé

BACKGROUND
Until recently, treatment options were limited for patients with acute myeloid leukemia and myelodysplastic syndrome (AML and MDS) who are ineligible for intensive chemotherapy. Owing to the condition's rapid progression, it is difficult to identify what is most important to patients when making treatment decisions. Patients' needs can be better addressed by gaining a deeper understanding of their perspectives, which is valuable in the decision-making process. The Food and Drug Administration recently encouraged the use of social media as a tool to gain insight on patients' perspectives regarding symptoms experienced and the impacts of their disease.
OBJECTIVE
This study aimed to use disease-specific social media posts by patients with AML or MDS who are ineligible for intensive chemotherapy and their caregivers to capture factors they feel are most important, and to provide current evidence to inform and characterize these perspectives.
METHODS
Posts by patients with AML or MDS and their caregivers were extracted from publicly available discussions on 3 large AML- or MDS-specific sites. These posts were manually reviewed to only include patients who are ineligible for intensive chemotherapy. A total of 1443 posts from 220 AML patients/caregivers and 2733 posts from 127 MDS patients/caregivers met the study inclusion criteria. A qualitative data analysis (QDA) of a sample of 85 patients'/caregivers' posts was conducted to identify themes, and a targeted QDA of posts from 79 users focused on treatment decision discussions. Posts were manually reviewed, and relevant text segments were coded and grouped into categories and overall themes.
RESULTS
Eighty-six percent (73/85) of users in the overall QDA had relevant information about the key objectives. The most commonly discussed treatment experience theme was the humanistic burden of AML or MDS in terms of emotional/physical impact and impact on family (86%, 63/73 of users), followed by treatment decisions (56%, 41/73) and unmet needs (50%, 37/73). In the QDA of treatment decisions, 60 posts from 45 users contained relevant information. Patients commonly reported the desire to reach specific milestones, including birthdays and weddings. They wished for a better quality of life over quantity of life, did not want the risk of suffering from side effects, and expressed a clear preference to be at home rather than in a hospital or care home.
CONCLUSIONS
This study was a novel application of disease-specific social media. It highlighted experiences in the current treatment of AML and MDS, including information gaps, patient/caregiver uncertainty, and the importance of understanding patients'/caregivers' goals and opinions. A clear finding from this research was the importance of reaching certain personal life goals and being at home with family and friends. The analysis showed that patients/caregivers face additional challenges, including humanistic impacts and a lack of information regarding treatment options.

Identifiants

pubmed: 31755871
pii: v21i11e14285
doi: 10.2196/14285
pmc: PMC6898885
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14285

Informations de copyright

©Alison Booth, Timothy Bell, Sonia Halhol, Shiyu Pan, Verna Welch, Evie Merinopoulou, Dimitra Lambrelli, Andrew Cox. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 22.11.2019.

Références

Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):625-636.e3
pubmed: 27686689
Future Oncol. 2019 Jun;15(16):1895-1909
pubmed: 30912462
Mediterr J Hematol Infect Dis. 2013 Jul 12;5(1):e2013050
pubmed: 23936621
Leuk Res. 2015 Feb;39(2):183-91
pubmed: 25577399
Curr Med Res Opin. 2018 Dec;34(12):2031-2039
pubmed: 29565196
Br J Haematol. 2015 Feb;168(3):361-70
pubmed: 25272332
Haematologica. 2012 Dec;97(12):1916-24
pubmed: 22773600
Clin Geriatr Med. 2016 Feb;32(1):155-73
pubmed: 26614866
J Patient Rep Outcomes. 2017;1(1):9
pubmed: 29757313
Blood Rev. 2018 Jan;32(1):81-87
pubmed: 28888621
Cancer. 2013 Aug 1;119(15):2720-7
pubmed: 23633441
Psychooncology. 2017 Dec;26(12):2063-2068
pubmed: 27862591
J Clin Oncol. 2011 May 20;29(15):1987-96
pubmed: 21483003
Oncol Ther. 2016;4(2):225-238
pubmed: 28261652
Cancer. 2018 Jan 1;124(1):145-152
pubmed: 28881384
Ann Hematol. 2015 Jul;94(7):1127-38
pubmed: 25791241
Front Oncol. 2015 Dec 14;5:280
pubmed: 26697412

Auteurs

Alison Booth (A)

Evidera, London, United Kingdom.

Timothy Bell (T)

Pfizer, New York, NY, United States.

Sonia Halhol (S)

Evidera, London, United Kingdom.

Shiyu Pan (S)

Evidera, London, United Kingdom.

Verna Welch (V)

Pfizer, New York, NY, United States.

Evie Merinopoulou (E)

Evidera, London, United Kingdom.

Dimitra Lambrelli (D)

Evidera, London, United Kingdom.

Andrew Cox (A)

Evidera, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH